Immune-based therapies slow HIV replication. (Experimental Treatments).
Publication: Skin & Allergy News
Publication Date: 01-JUN-03
Author: Mahoney, Diana
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
BOSTON -- An interferon-[alpha] agent and a recombinant canarypox vaccine are among the latest experimental therapies to control HIV replication in clinical studies by boosting the immune systems of early-stage and chronically infected HIV patients.
Pegylated interferon alfa-2b significantly suppressed viral replication and boosted immune responses in a small group of treatment-naive HIV patients in a pilot study presented at the 10th Conference on Retroviruses and Opportunistic Infections.
Of 10 asymptomatic HIV-infected patients who had not initiated antiretroviral therapy, 5 were treated with 80 [micro]g pegylated interferon alfa-2b...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
